Danielle M. Burgenske

Mayo Clinic, Rochester

Research Area

Biography

Danielle M. Burgenske has not added Biography.
If you are Danielle M. Burgenske and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2026

Other Publications

Article	Year
Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors. Cancer research\| PubMed ID: 31273061	2019
Molecular profiling of long-term IDH-wildtype glioblastoma survivors. Neuro-oncology\| PubMed ID: 31346613	2019
Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks. Cancer research\| PubMed ID: 34016623	2021
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. Neuro-oncology\| PubMed ID: 34050676	2021
Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines. Neuro-oncology\| PubMed ID: 34107029	2021
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules. Neuro-oncology\| PubMed ID: 34232318	2022
Multimodal platform for assessing drug distribution and response in clinical trials. Neuro-oncology\| PubMed ID: 34383057	2022
Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 34556535	2021
RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma. Neuro-oncology\| PubMed ID: 35231103	2022
Central Nervous System Delivery of the Catalytic Subunit of DNA-Dependent Protein Kinase Inhibitor Peposertib as Radiosensitizer for Brain Metastases. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 35370138	2022
Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy. Science advances\| PubMed ID: 35486732	2022
Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts. Neuro-oncology advances\| PubMed ID: 36071925	2022
Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 36137710	2022
WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models. Neuro-oncology advances\| PubMed ID: 37324218	2023
Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma. Molecular cancer therapeutics\| PubMed ID: 37828724	2024
Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts. Molecular cancer therapeutics\| PubMed ID: 38224566	2024
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization. Science translational medicine\| PubMed ID: 38354228	2024
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 38743766	2024
Preclinical Systemic Pharmacokinetics, Dose Proportionality, and Central Nervous System Distribution of the ATM Inhibitor WSD0628, a Novel Radiosensitizer for the Treatment of Brain Tumors. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 38858089	2024
Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of ... The Journal of pharmacology and experimental therapeutics\| PubMed ID: 39284626	2024
DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits. Molecular cancer therapeutics\| PubMed ID: 39440433	2025
Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628. Molecular cancer therapeutics\| PubMed ID: 39559836	2025
selection of anti-glioblastoma DNA aptamers in an orthotopic patient-derived xenograft model. NAR cancer\| PubMed ID: 39968526	2025
The impact of therapeutic radiation on drug distribution across the blood-brain barrier in normal mouse brain and orthotopic glioblastoma tumors. Neuro-oncology\| PubMed ID: 40163716	2025
The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts. Neuro-oncology\| PubMed ID: 40230030	2025
Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 40591434	2025
Optimizing procedures for ocular radiation injury studies in the tree shrew. Exploration of targeted anti-tumor therapy\| PubMed ID: 41357135	2025
Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts. Neuro-oncology advances\| PubMed ID: 41664821	2026